论文部分内容阅读
目的 探讨p5 3、Bcl 2和nm 2 3基因蛋白表达与非小细胞肺癌 (NSCLC)临床病理特征的关系。方法 应用免疫组织化学S -P法检测 5 6例NSCLC组织中 p5 3、Bcl 2和nm2 3基因蛋白的表达。 结果 p5 3、Bcl 2和nm2 3蛋白在NSCLC中的阳性率分别为 5 1.8%、3 2 .1%、5 3 .6% ;在肺鳞癌、腺癌中p5 3阳性表达随病理分级升高而增加 (P <0 .0 5 ) ,而Bcl 2阳性表达则随病理分级升高而降低 (P <0 .0 5 ) ;NSCLC淋巴结转移阳性组nm2 3阳性率显著低于淋巴结无转移组 (P <0 .0 5 )。结论 p5 3、Bcl 2和nm 2 3基因蛋白的检测对预测NSCLC淋巴结转移及判断预后有重要意义。
Objective To investigate the relationship between the expression of p53, Bcl2 and nm23 protein and the clinicopathological features of non-small cell lung cancer (NSCLC). Methods The expressions of p53, Bcl2 and nm23 protein in 56 NSCLC tissues were detected by immunohistochemical S-P method. Results The positive rates of p5 3, Bcl 2 and nm23 proteins in NSCLC were 5 1.8%, 32.1% and 53.3% respectively. The positive expression of p5 3 in lung squamous cell carcinoma and adenocarcinoma was positively correlated with pathological grade (P <0.05), while the positive expression of Bcl 2 decreased with the pathological grade (P0.05). The positive rate of nm23 in NSCLC patients with lymph node metastasis was significantly lower than that without lymph node metastasis (P <0. 05). Conclusion The detection of p53, Bcl2 and nm23 gene proteins is of great significance in predicting lymph node metastasis and prognosis of NSCLC.